Literature DB >> 15837627

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Ross L Levine1, Martha Wadleigh, Jan Cools, Benjamin L Ebert, Gerlinde Wernig, Brian J P Huntly, Titus J Boggon, Iwona Wlodarska, Jennifer J Clark, Sandra Moore, Jennifer Adelsperger, Sumin Koo, Jeffrey C Lee, Stacey Gabriel, Thomas Mercher, Alan D'Andrea, Stefan Fröhling, Konstanze Döhner, Peter Marynen, Peter Vandenberghe, Ruben A Mesa, Ayalew Tefferi, James D Griffin, Michael J Eck, William R Sellers, Matthew Meyerson, Todd R Golub, Stephanie J Lee, D Gary Gilliland.   

Abstract

Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM) are clonal disorders arising from hematopoietic progenitors. An internet-based protocol was used to collect clinical information and biological specimens from patients with these diseases. High-throughput DNA resequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations. Molecular and cytogenetic analyses demonstrated that homozygous mutations were due to duplication of the mutant allele. JAK2V617F was also identified in granulocyte DNA samples from 37 of 115 ET and 16 of 46 MMM patients, but was not observed in 269 normal individuals. In vitro analysis demonstrated that JAK2V617F is a constitutively active tyrosine kinase.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837627     DOI: 10.1016/j.ccr.2005.03.023

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  981 in total

1.  Lnk constrains myeloproliferative diseases in mice.

Authors:  Alexey Bersenev; Chao Wu; Joanna Balcerek; Jiang Jing; Mondira Kundu; Gerd A Blobel; Kudakwashe R Chikwava; Wei Tong
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

Review 2.  A potential role of ruxolitinib in leukemia.

Authors:  Kiran Naqvi; Srdan Verstovsek; Hagop Kantarjian; Farhad Ravandi
Journal:  Expert Opin Investig Drugs       Date:  2011-06-03       Impact factor: 6.206

3.  Critical requirement for Stat5 in a mouse model of polycythemia vera.

Authors:  Dongqing Yan; Robert E Hutchison; Golam Mohi
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

4.  Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity.

Authors:  Zhe Li; Shu Xing; Shaofeng Wang; Wanting Tina Ho; Zhizhuang Joe Zhao
Journal:  Exp Hematol       Date:  2007-08-30       Impact factor: 3.084

5.  JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.

Authors:  Sven Schwemmers; Britta Will; Cornelius F Waller; Khadija Abdulkarim; Peter Johansson; Björn Andreasson; Heike L Pahl
Journal:  Exp Hematol       Date:  2007-08-30       Impact factor: 3.084

6.  A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers.

Authors:  Yoichiro Ogama; Tomoko Mineyama; Asuka Yamamoto; Margaret Woo; Naomi Shimada; Taro Amagasaki; Kazuto Natsume
Journal:  Int J Hematol       Date:  2013-02-05       Impact factor: 2.490

Review 7.  Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.

Authors:  Sara C Meyer; Ross L Levine
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 8.  Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.

Authors:  Laura Breda; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

9.  Intrinsic resistance to JAK2 inhibition in myelofibrosis.

Authors:  Anna Kalota; Grace R Jeschke; Martin Carroll; Elizabeth O Hexner
Journal:  Clin Cancer Res       Date:  2013-02-05       Impact factor: 12.531

10.  Functional conservation of erythropoietin signaling in zebrafish.

Authors:  Noëlle Paffett-Lugassy; Nelson Hsia; Paula G Fraenkel; Barry Paw; Irene Leshinsky; Bruce Barut; Nathan Bahary; Jaime Caro; Robert Handin; Leonard I Zon
Journal:  Blood       Date:  2007-06-19       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.